A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 2
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE
- Evidence population
- Human clinical study registration
- Participants
- 78
- Population
- ALL · 50 Years to 80 Years
- Duration
- 2020-07-24 to 2022-11-15
- Intervention
- Sanhuangjingshimingwan; Sanhuangjingshimingwan Placebo
- Comparator
- Sanhuangjingshimingwan Placebo group
- Outcomes measured
- The average number of reinjections — at week 24; The percentage of subjects in both arms receiving reinjection of Anti-VEGF injection — at screening;at week 4;at week 8…; The average number of days between the second injection and baseline injection — at screening;at week 4;at week 8;at we…; Change from baseline in BCVA — at screening;at week 4;at week 8;at week 12;at week 16;at week 20;at week 24; The BCVA increasing >5, >10 and > 15 letters change from baseline — at screening;at week 4;at week 8;at week 12;at week…; The BCVA decreasing<5, <10 and < 15 letters change form baseline — at screening;at week 4;at week 8;at week 12;at week…; The BCVA decreasing≥15, ≥30 letters change form baseline — at week 24; Change from Baseline in Central Retinal Thickness (CRT) — at screening;at week 4;at week 8;at week 12;at week 16;at wee…; Change from Baseline in Choroidal Neovascularization (CNV) area — at screening;at week 4;at week 8;at week 12;at week 1…; Change from Baseline in leakage area — at week 24; Change from Baseline in the number of polypoid choroidal vasculopathy(PCV) and Branching vascular network(BVN) area — a…; Change from Baseline in TCM(Traditional Chinese Medicine) syndrome scores — at screening;at week 4;at week 8;at week 12…; Change from Baseline in the effective TCM syndrome scores — at screening;at week 4;at week 8;at week 12;at week 16;at w…
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.